| TM | Type of malignancy | Differential diagnosis | Prognosis/staging | Treatment monitoring/surveillance |
| Tg | Thyroid | x | | x | Calcitonin | Thyroid (medullary) | x | | x | β2M (beta-2-microglobulin) | Multiple myeloma, CLL | | x | | CEA | CRC, pancreatic, gastric/gastroesophageal AC, esophageal AC, NSCLC AC, breast, endometrial, thyroid, c-cell | | | x | CA 125 | Ovarian, breast, omental carcinomatosis | x | | x | HE4 | Ovarian, NSCLC, endometrial | x | | x | Beta-HCG | GCT, choriocarcinoma, urothelial | x | x | x | AFP (alpha-feto protein) | HCC, GCT | x | x | x | CA 15-3 | Breast, NSCLC AC | | x | x | CA 19-9 | Pancreatic, biliary tract, upper GI | | x | x | CA 72-4 | Upper GI, mucinous ovarian | | | x | CYFRA 21-1 | NSCLC, esophageal, HNSCC, pancreatic, bladder | x | | x | S100 | Malignant melanoma | | | x | NSE | SCLC, NET, neuroblastoma | x | | x | ProGRP | SCLC, thyroid medullary | x | x | x | Chromogranin A | SCLC, NET | x | | x | PSA/free PSA | Prostate | x | x | x | SCCA | Cervix SCC, NSCLC SCC, esophageal SCC, HNSCC | x | | | Ig (immunoglobulin) | Multiple myeloma | | | x | LC (light chains) | Multiple myeloma | x | | x | Her-2-neu | Breast cancer | | | x | TK | Multiple myeloma, CLL | x | x | x |
|
|
AC, adenocarcinoma; SCC, squamous cell carcinoma; CLL, chronic lymphocytic leukemia; HNSCC, head and neck squamous cell carcinoma; GCT, germ-cell tumor; GI, gastrointestinal; NET, neuroendocrine tumors; TK, thymidine kinase; Tg, thyroglobulin.
|